CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

NCT06433362 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

115

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: CMOEP

Sponsor

Tianjin Medical University Cancer Institute and Hospital